Kirschfink M - Search Results

1

Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.

Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B. Licht C, et al. Among authors: kirschfink m. Am J Kidney Dis. 2005 Feb;45(2):415-21. doi: 10.1053/j.ajkd.2004.10.018. Am J Kidney Dis. 2005. PMID: 15685522

2

Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Licht C, et al. Among authors: kirschfink m. Kidney Int. 2006 Jul;70(1):42-50. doi: 10.1038/sj.ki.5000269. Epub 2006 Apr 12. Kidney Int. 2006. PMID: 16612335 Free article.

3

Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M, Zipfel PF, Goodship JA, Zimmerhackl LB. Gerber A, et al. Among authors: kirschfink m. Pediatr Nephrol. 2003 Sep;18(9):952-5. doi: 10.1007/s00467-003-1192-3. Epub 2003 Jun 26. Pediatr Nephrol. 2003. PMID: 12836093

4

C3 deposition glomerulopathy due to a functional factor H defect.

Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C. Habbig S, et al. Among authors: kirschfink m. Kidney Int. 2009 Jun;75(11):1230-1234. doi: 10.1038/ki.2008.354. Epub 2008 Jul 16. Kidney Int. 2009. PMID: 18633337 Free article. No abstract available.

5

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Mache CJ, et al. Among authors: kirschfink m. Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25. Clin J Am Soc Nephrol. 2009. PMID: 19556379 Free PMC article.

6

Successful treatment of DEAP-HUS with eculizumab.

Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. Noone D, et al. Among authors: kirschfink m. Pediatr Nephrol. 2014 May;29(5):841-51. doi: 10.1007/s00467-013-2654-x. Epub 2013 Nov 20. Pediatr Nephrol. 2014. PMID: 24249282

7

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT. Schalk G, et al. Among authors: kirschfink m. Pediatr Nephrol. 2015 Jun;30(6):1039-42. doi: 10.1007/s00467-015-3078-6. Epub 2015 Mar 10. Pediatr Nephrol. 2015. PMID: 25752761

8

Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, Habbig S. Hackl A, et al. Among authors: kirschfink m. Pediatr Nephrol. 2017 Jun;32(6):1081-1087. doi: 10.1007/s00467-017-3612-9. Epub 2017 Feb 20. Pediatr Nephrol. 2017. PMID: 28220235 Review.

9

The Case | A 78-year-old woman with acute kidney injury and hemolytic anemia.

Zecher D, Banas B, Büttner-Herold M, Kirschfink M, Zipfel PF. Zecher D, et al. Among authors: kirschfink m. Kidney Int. 2019 Feb;95(2):473-474. doi: 10.1016/j.kint.2018.10.013. Kidney Int. 2019. PMID: 30665579 Free article. No abstract available.

10

MPGN II--genetically determined by defective complement regulation?

Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. Licht C, et al. Among authors: kirschfink m. Pediatr Nephrol. 2007 Jan;22(1):2-9. doi: 10.1007/s00467-006-0299-8. Epub 2006 Sep 23. Pediatr Nephrol. 2007. PMID: 17024390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters